



Published in final edited form as:

*Stroke*. 2018 September ; 49(9): 2237–2240. doi:10.1161/STROKEAHA.118.022128.

## Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding Stroke

Chen Jin, MD, MSc, Ryan J. Huang, BA, Eric D. Peterson, MD, MPH, Daniel T. Laskowitz, MD, MHS, Adrian F. Hernandez, MD, MHS, Jerome J. Federspiel, MD, PhD, Lee H. Schwamm, MD, Deepak L. Bhatt, MD, MPH, Eric E. Smith, MD, MPH, Gregg C. Fonarow, MD, Ying Xian, MD, PhD

Coronary Heart Disease Center, Fuwai Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China (C.J.); Duke Clinical Research Institute, Durham, NC (Y.X., A.F.H., E.D.P.); Department of Neurology, Duke University Medical Center, Durham, NC (Y.X., D.T.L.); School of Medicine, Duke University, Durham, NC (R.J.H.); Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD (J.J.F.); Division of Neurology, Massachusetts General Hospital, Boston (L.H.S.); Brigham and Women's Hospital Heart and Vascular Center Boston, MA (D.L.B.); Harvard Medical School, Boston, MA (D.L.B.); Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Alberta, Canada (E.E.S.); and Division of Cardiology, University of California, Los Angeles (G.C.F.).

### Abstract

**Background and Purpose**—Although there are no trials or large cohorts to inform clinical care, current guidelines caution against giving intravenous tPA (tissue-type plasminogen activator) to patients with acute ischemic stroke who are taking non–vitamin K antagonist oral anticoagulants (NOACs). We performed a literature review of intravenous tPA in patients treated with NOACs preceding stroke.

**Methods**—A literature search of PubMed was performed encompassing January 2010 to March 2018. Patient characteristics, timing of last medication intake, laboratory testing, use of reversal, and outcomes 3 months after discharge were summarized.

**Results**—We identified 55 studies with 492 NOAC patients receiving tPA (dabigatran, 181; rivaroxaban, 215; apixaban, 40; and unspecified NOAC, 56). Among patients with complete data, the median time from the last NOAC intake to symptom onset was 8 hours (interquartile range, 2.5–14.5), with 55.2% (80/145) within 12 hours. Few patients underwent sensitive laboratory tests, such as thrombin time, diluted thrombin time, or anti-Xa assays before tPA administration. The overall observed rates of symptomatic intracranial hemorrhage, mortality, and favorable outcomes (National Institutes of Health Stroke Scale score,  $\geq 1$ ; modified Rankin Scale score, 0–2; or neurological improvement in the National Institutes of Health Stroke Scale score,  $\geq 8$  points) were 4.3% (20/462), 11.3% (48/423), and 43.7% (164/375), respectively. Among dabigatran-treated

---

Correspondence to Ying Xian, MD, PhD, Duke Clinical Research Institute, Durham, NC 27705. ying.xian@duke.edu.

The online-only Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.022128>.

patients, reversal with idarucizumab was associated with fewer symptomatic intracranial hemorrhage (4.5% [2/44] versus 7.4% [8/108]; unadjusted odds ratio, 0.60; 95% CI, 0.12–2.92), death (4.5% [2/44] versus 12.0% [13/108]; unadjusted odds ratio, 0.35; 95% CI, 0.08–1.61), and more favorable outcomes (79.1% [34/43] versus 39.2% [29/74]; unadjusted odds ratio, 5.86; 95% CI, 2.45–14.00), although the differences were not statistically significant for symptomatic intracranial hemorrhage and death.

**Conclusions**—These preliminary observations suggest that tPA may be reasonably well tolerated without prohibitive risks of bleeding complications in selected patients on NOACs. Reversal of anticoagulant effects by idarucizumab for dabigatran-treated patients before tPA is an emerging strategy that was associated with more favorable outcomes.

## Keywords

apixaban; dabigatran; humans; intracranial hemorrhages; rivaroxaban

---

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in high-risk patients with atrial fibrillation. However, increasing NOAC adoption also challenges clinicians when treating patients who experience an acute ischemic stroke while taking these medications. Although successful thrombolysis has been reported, the safety of intravenous tPA (tissue-type plasminogen activator) in NOAC patients has not been firmly established and may be harmful (class III: harm; level of evidence C-expert opinion).<sup>1</sup> In the absence of confirmatory research, we summarized all evidence from the literature and provided an up-to-date understanding of intravenous tPA in patients taking NOACs preceding stroke.

## Methods

The authors declare that all supporting data are available within the article and its online-only Data Supplement. A literature review was conducted according to PRISMA guidelines and performed between June 2015 and March 2018 using PubMed with the term stroke and thrombolysis/thrombolytic therapy/recombinant tissue plasminogen activator/tissue plasminogen activator/alteplase/r-tPA/tPA/recanalization, combined with names of individual NOACs (dabigatran, rivaroxaban, apixaban, or edoxaban), novel oral anticoagulant, non-vitamin K antagonist oral anticoagulant, direct oral anticoagulant, direct thrombin inhibitor, factor Xa inhibitor, or idarucizumab as title words or key words. The study flow diagram is shown in Figure I in the online-only Data Supplement. We limited to studies in humans, published in English. Because indications of endovascular treatment may not be generalizable to intravenous approach, we focused on intravenous tPA when data on route were available. A standard form was developed to extract patient demographics, key time intervals, laboratory tests, initial National Institutes of Health Stroke Scale, use of idarucizumab, symptomatic intracranial hemorrhage (sICH), and outcomes 3-month follow-up. Based on the NINDS trial criteria and data availability,<sup>2</sup> National Institutes of Health Stroke Scale score  $\geq 1$ , modified Rankin Scale score 0 to 2, or neurological improvement in National Institutes of Health Stroke Scale score  $\geq 8$  points were considered as favorable outcome.

Except for 2 large multicenter cohorts,<sup>3,4</sup> most studies were case reports or case series. Because of potential publication bias, treatment selection, small sample size, lack of control, or lack of adjusted results, we did not perform a meta-analysis by pooling study odds ratios. Instead, we summarized characteristics and reported outcomes in the entire sample. Because the results of each NOAC are not comparable in this type of review, individual NOAC outcomes were not reported separately, except for dabigatran with idarucizumab because it represents an up-to-date information. The Institutional Review Board of Duke University approved the study.

## Results

### Baseline Characteristics

We identified 55 studies with a total of 492 NOAC patients (181 dabigatran, 215 rivaroxaban, 40 apixaban, and 56 unspecified NOAC agent) receiving stroke recanalization therapy (Table I in the online-only Data Supplement). Among patients with complete individual-level data, the median age was 77 years (interquartile range, 68–83; n=73), the median National Institutes of Health Stroke Scale score was 10 (interquartile range, 6–16; n=75), and the median time from last NOAC intake to stroke onset was 8 hours (interquartile range, 2.5–14.5; n=39; Table 1). Based on descriptions of the case presentation, 55.2% (80/145) took NOAC within 12 hours preceding stroke onset, 33.9% (43/127) within 13 to 24 hours, and 7.7% (10/130) >24 hours. The most commonly used coagulation test was aPTT, with 27.4% (34/124) of patients with prolonged aPTT. Fewer patients underwent sensitive tests, such as thrombin time (85.2% [23/27] with prolonged thrombin time), diluted thrombin time, dabigatran concentration for dabigatran (39.4%; 37/94), or anti-Xa assays for rivaroxaban and apixaban (47.3%; 43/91). No study reported using ecarin clotting time to detect the presence of dabigatran.

### Clinical Outcomes

The overall observed rates of sICH, mortality, and favorable outcomes were 4.3% (20/462), 11.3% (48/423), and 43.7% (164/375), respectively (Table 2). Among dabigatran-treated patients, reversal with idarucizumab was associated with fewer sICH (4.5% [2/44] versus 7.4% [8/108]; unadjusted odds ratio, 0.60; 95% CI, 0.12–2.92), death (4.5% [2/44] versus 12.0% [13/108]; unadjusted odds ratio, 0.35; 95% CI, 0.08–1.61), and more favorable outcomes (79.1% [34/43] versus 39.2% [29/74]; unadjusted odds ratio, 5.86; 95% CI, 2.45–14.00), although the differences were not statistically significant for sICH and death.

## Discussion

The current guidelines caution against administering intravenous tPA to patients taking NOACs unless sensitive laboratory tests are normal or the last intake of NOACs is >48 hours before stroke.<sup>1</sup> However, this recommendation is complex to implement because of the lack of rapidly available sensitive tests. Global coagulation tests, such as PT, aPTT, and INR are not specific for NOACs.<sup>5</sup> Indeed, few patients in this review received tPA based on sensitive test results, such as thrombin time or anti-Xa assays. Interestingly, most patients with last NOAC intake documented had NOAC within 24 hours before stroke (55.2% within 12 hours

and 33.9% between 13 and 24 hours), which was shorter than the recommended 48-hour window. Although few cases in this review were treated with tPA according to guideline recommendations, the observed sICH rates seem to be comparable with those reported in non-anticoagulated patients in clinical trials. Therefore, this review contributes to the growing body of evidence that patients taking NOACs may not have an increased bleeding risk after tPA administration.<sup>6</sup>

With the introduction of idarucizumab in 2015 and andexanet alfa in 2018, patients taking NOACs may undergo reversal of anticoagulation, potentially reducing bleeding risk. In our review of 152 cases with dabigatran, those reversed with idarucizumab appeared less likely to bleed (4.5% versus 7.4%) and die (4.5% versus 12.0%) and more likely to have favorable outcomes (79.1% versus 39.2%) than those not. These findings suggest that intravenous tPA after idarucizumab reversal is a reasonable option to consider in patients on dabigatran even though a prothrombotic effect cannot be completely excluded.<sup>7</sup> Further studies are needed to evaluate the safety and efficacy of anticoagulation reversal before tPA administration.

Our study has limitations. First, this review is based mostly on case reports or case series. Publication bias and treatment selection are likely significant and potentially overestimate or underestimate the true bleeding risk. Second, small sample size, lack of control groups, and only aggregate data in some studies prevent us from doing risk adjustment or running suitable meta-analyses. Third, owing to the nature of case reports and word limits imposed by various journals, patient-level details are often incomplete. Therefore, a direct comparison between NOAC versus no oral anticoagulants, NOAC versus warfarin, or between each individual NOAC agent cannot be made.

In conclusion, this present review suggests that use of intravenous tPA in selected patients with acute ischemic stroke treated with NOACs is feasible and appears to be well tolerated without prohibitive risks for bleeding complications. Reversal of anticoagulant effects by idarucizumab is an emerging strategy that was associated with more favorable outcomes. Further prospective studies and clinical trials are needed to evaluate the safety and efficacy of tPA in patients with ischemic stroke who are taking NOACs.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Sources of Funding

This study was supported, in part, by awards from the American Heart Association (13CRP14410024/14SDG20460081). The funding organizations had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation of the manuscript.

### Disclosures

Dr Xian reports research grants from the American Heart Association, Daiichi Sankyo, Janssen Pharmaceuticals, and Genentech and honorarium from Portola. Dr Hernandez reports other research support from Daiichi, Janssen, and Genentech and is a consultant to AstraZeneca and Bayer. Dr Schwamm reports other research support from NINDS (principal investigator of an investigator-initiated study of extended-window intravenous thrombolysis funded by the National Institutes of Neurological Disorders and Stroke [<http://www.clinicaltrials.gov/show/NCT01282242>]) and Genentech (Genentech provides alteplase free of charge to Massachusetts General Hospital, as well as supplemental per patient payments to participating sites in an investigator-initiated trial of extended-window

intravenous thrombolysis funded by the National Institutes of Neurological Disorders and Stroke [<http://www.clinicaltrials.gov/show/NCT01282242>]; serves as a stroke systems consultant to the Massachusetts Department of Public Health; serves as a scientific consultant to Penumbra on trial design and conduct to Penumbra (data and safety monitoring committee, Separator 3D and MIND trial); and serves as a scientific consultant to Medtronic on trial design and conduct to Medtronic (Victory AF, REACT AF, and Stroke AF trials). Dr Bhatt reports research funding from Abbott, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, and The Medicines Company; unfunded research support from FlowCo, Merck, PLx Pharma, and Takeda; honoraria from the American College of Cardiology (ACC; Senior Associate Editor, Clinical Trials and News, [ACC.org](http://www.acc.org); Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, *Journal of Invasive Cardiology*), *Journal of the American College of Cardiology* (Guest Editor; Associate Editor), Population Health Research Institute (COMPASS clinical trial steering committee funded by Bayer), Slack Publications (Chief Medical Editor, *Cardiology Today's Intervention*), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees); belongs to the advisory board at Cardax, Medscape Cardiology, Regado Biosciences, and Elsevier Practice Update Cardiology; belongs to the board of directors at Boston VA Research Institute and Society of Cardiovascular Patient Care; was chair at the American Heart Association Quality Oversight Committee; belongs to the data monitoring committees at Cleveland Clinic, Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute. *Clinical Cardiology* (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), and VA CART Research and Publications Committee (Chair); reports royalties from Elsevier (Editor, *Cardiovascular Intervention: A Companion to Braunwald's Heart Disease*); is a site coinvestigator for trials sponsored by Biotronik, Boston Scientific, Svelte, and St. Jude Medical (now Abbott); and is a trustee at ACC. Dr Smith reports consulting for Portola. Dr Fonarow reports grants from PCORI and National Institutes of Health, consulting at Janssen and Medtronic, and is an UCLA Employee, which holds a patent on stroke retriever devices. Dr Peterson reports receiving a research grant from Janssen, honoraria from Janssen, and has institutional conflict of interest with DCRI research funding from Janssen, Bristol-Myers Squibb, and Pfizer. The other authors report no conflicts.

## References

1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al.; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2018;49:e46–e110. doi: 10.1161/STR.000000000000158 [PubMed: 29367334]
2. National Institute of Neurological Disorders and Stroke rt-Pa Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med*. 1995;333:1581–1588. doi: 10.1056/NEJM199512143332401 [PubMed: 7477192]
3. Seiffge DJ, Hooff RJ, Nolte CH, Béjot Y, Turc G, Ikenberg B, et al.; NOACISP Study Group\*. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. *Circulation*. 2015;132:1261–1269. doi: 10.1161/CIRCULATIONAHA.115.015484 [PubMed: 26232277]
4. Xian Y, Federspiel JJ, Hernandez AF, Laskowitz DT, Schwamm LH, Bhatt DL, et al. Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non-vitamin K antagonist oral anticoagulants before stroke. *Circulation*. 2017;135:1024–1035. doi: 10.1161/CIRCULATIONAHA.116.023940 [PubMed: 28119380]
5. Ebner M, Birschmann I, Peter A, Härtig F, Spencer C, Kuhn J, et al. Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions. *Stroke*. 2017;48:2457–2463. doi: 10.1161/STROKEAHA.117.017981 [PubMed: 28775134]
6. Tsivgoulis G, Safouris A. Intravenous thrombolysis in acute ischemic stroke patients pretreated with non-vitamin K antagonist oral anticoagulants: an editorial review. *Stroke*. 2017;48:2031–2033. doi: 10.1161/STROKEAHA.117.017206 [PubMed: 28536167]
7. Diener HC, Bernstein R, Butcher K, Campbell B, Cloud G, Davalos A, et al. Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. *Int J Stroke*. 2017;12:9–12. doi: 10.1177/1747493016669849 [PubMed: 27694315]

**Table 1.**

## Baseline Characteristics

	Measures
NOACs	492 <sup>*</sup>
Dabigatran	181/492 (36.8%)
Reversal with idarucizumab	44/181 (24.2%)
Rivaroxaban	215/492 (43.7%)
Apixaban	40/492 (8.1%)
NOACs not specified	56/492 (11.4%)
Age, y <sup>†</sup>	Median, 77 (IQR, 68–83)
Women	233/492 (47.4%)
NOAC last intake before stroke, h <sup>†</sup>	Median, 8 (IQR, 2.5–14.5)
12	80/145 (55.2%)
13–24	43/127 (33.9%)
>24	10/130 (7.7%)
Precise time/range not reported	347/492 (70.5%)
Laboratory <sup>†</sup>	
Prolonged PT	7/16 (43.8%)
Prolonged aPTT	34/124 (27.4%)
Prolonged TT in dabigatran	23/27 (85.2%)
TT, dTT, or dabigatran concentration in dabigatran	37/94 (39.4%)
Anti-Xa assay in rivaroxaban or apixaban	43/91 (47.3%)
NIHSS on admission	Median, 10 (IQR, 6–16) <sup>†</sup>

dTT indicates diluted thrombin time; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulants; and TT, thrombin time.

\* Includes 30 patients receiving intra-arterial treatment.

<sup>†</sup> Among patients with complete individual-level data.

**Table 2.**

Clinical Outcomes

NOACs	sICH	Death*	Favorable Outcomes <sup>*,†</sup>
Overall	20/462 (4.3% [2.7–6.4])	48/423 (11.3% [8.6–14.6])	164/375 (43.7% [38.8–48.8])
Dabigatran			
Reversal with idarucizumab	2/44 (4.5% [0.8–13.4])	2/44 (4.5% [0.8–13.4])	34/43 (79.1% [65.4–89.3])
Without idarucizumab	8/108 (7.4% [3.5–13.4])	13/108 (12.0% [6.8–19.0])	29/74 (39.2% [28.6–50.5])

mRS indicates modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulants; and sICH, symptomatic intracranial hemorrhage.

\* At discharge or 3-month follow-up.

† NIHSS, 1; mRS, 0–2; or improvement in NIHSS score, 8 points.